[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiovascular-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiovascular-diseases":664},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,432,0,25,[9,49,74,88,107,126,154,180,211,239,259,292,315,336,355,381,409,431,456,511,542,563,601,623,645],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100053350",false,"NCT07613099","Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET\u002FCT Imaging","Evaluation of Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74 PET\u002FCT Imaging)","* INCLUSION CRITERIA\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Participant \\>=18 years old\n4. Has a specific diagnosis of a cardiopulmonary and\u002For vascular disease that puts them at risk of developing or having developed tissue fibrosis.\n5. Has undergone prior imaging of lungs, heart, and\u002For vasculature with chest CT\n6. Able to lie on the PET\u002FCT scanner for imaging up to 45 minutes.\n7. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 4 weeks after the end of FAPI-PET\u002FCT or the FDG PET\u002FCT scan.\n8. For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner during study participation and for an additional 4 weeks after the end of FAPI-PET\u002FCT or the FDG PET\u002FCT scan.\n9. Ability of subject to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. History of allergic reactions attributed to compounds of similar chemical or biologic composition to 18F-FAPI-74 or other agents used in the study.\n2. Uncontrolled intercurrent illness, factors, or social situations that would limit compliance with study requirements\n3. Pregnancy or lactation\n4. Women able to become pregnant or men actively trying to father a child and are unwilling to use an effective form of birth control during the study and 4 weeks after the last 18F-FAPI-74 PET\u002FCT scan or the FDG PET\u002FCT scan.\n5. Subjects with severe claustrophobia unresponsive to oral anxiolytics.\n6. Subjects weighing \\> 350 lbs (weight limit for PET scanner table), or unable to fit within the imaging gantry","ALL","18 Years","100 Years",{"count":20,"type":21},210,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Background:\n\nInjury or diseases of the heart and lung can sometimes cause scar tissue (fibrosis) to build up in those organs. Current imaging scans can see this scar tissue once it has formed, but researchers want to find a way to detect the fibrosis in its earliest stages, while there might still be time to prevent serious damage. A new tracer (a radioactive substance injected during imaging scans) may be able to help.\n\nObjective:\n\nTo test a new tracer (18F-FAPI-74) during imaging scans in people with heart or lung disease.\n\nEligibility:\n\nPeople aged 18 years and older with lung or heart disease that may cause scarring in those organs.\n\nDesign:\n\nParticipants will have 6 clinic visits over 2 years.\n\nParticipants will be screened: They will have blood tests and tests of their heart and lung function. Those with heart disease will have a magnetic resonance imaging (MRI) scan of the heart.\n\nThe study tracer will be used with positron emission tomography (PET)\u002Fcomputed tomography (CT) scans. The study tracer will be injected into a vein in the arm. Participants will lie on a padded bed that slides through a donut-shaped machine.\n\nParticipants will have scans with the study tracer 2 times, 8 to 12 months apart. They will also have standard CT scans and blood tests during these visits. They will also have blood tests at 3 and 6 months between these visits.\n\nParticipants will have a follow-up visit after 18 to 24 months. The study scans, MRI and standard CT scans, and lung function tests may be repeated....",[27,28,29,30,31,32],"Allogeneic Stem Cell Transplantation","Lung Allograft Transplantation","Interstitial Lung Disease","Acute Lung Injury","Pulmonary Arterial Hypertension","Cardiovascular Diseases",[34,35],"Fibroblast activation protein (FAP) FAPI\u002FPET","Fibrotic Disease Activity","NOT_YET_RECRUITING","2026-07-10",{"date":39,"type":40},"2026-07-13","ACTUAL",{"date":42,"type":21},"2026-07-16",{"date":44,"type":21},"2033-05-26",{"name":46,"class":47},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",1,{"id":50,"slug":4,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":48},"100053824","NCT02604563","Aging, Geriatric Syndromes and Clonal Hematopoiesis","Inclusion Criteria:\n\n* At least 50 years of age.\n* Able to understand written and spoken English.\n* Able to understand and willing to sign an IRB-approved written informed consent document (or that of a legally authorized representative, if applicable for the trauma cohort)\n\nExclusion Criteria:\n\n* Inability or unwillingness to complete health questionnaire (with the exception of hip and knee replacement participants).\n* History of a recent (\\\u003C30 days) acute viral illness.\n* Current cancer diagnosis and currently receiving chemotherapy or undergoing radiation therapy. A prior history of cancer is allowed if the participant completed therapy \\> 1 year prior to enrollment; participants with a prior diagnosis of cancer will be asked to sign a release of information for the research team to obtain records regarding their prior cancer treatment.\n* Current use of drugs that cause DNA damage (e.g. Cytoxan, azathioprine, etc.) for the treatment of a non-malignant disease.\n* Vulnerable populations (e.g. prisoners).\n* Known infection with Hepatitis B or C, HTLV, or HIV.\n* Additional exclusion for optional bone marrow aspirate\u002Fbiopsy substudy:\n\n  * Use of medications for anticoagulation or \"blood thinning\" including warfarin, low molecular weight heparins (enoxaparin, daltaparin) or direct-acting oral anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban or betrixaban)\n  * allergy to lidocaine or other local anesthetics.",true,"50 Years",{"count":57,"type":21},2000,"OBSERVATIONAL","In this study the investigators will incorporate a wide range of clinical variables associated with aging and cardiovascular disease to determine whether they are associated with mutation status independent of chronologic age. Clinically, aging can be operationalized using geriatric assessment, which entails a comprehensive multi-dimensional assessment of the health of an older adult, including measures of comorbidity, polypharmacy, functional status, cognition, depression, falls, social activities and social support. Given that aging is heterogeneous, geriatric assessment allows greater specificity for aging than chronological age alone.",[61,62,63,32],"Geriatrics","Aged","Geriatric Syndromes","RECRUITING","2026-07-09",{"date":39,"type":40},{"date":68,"type":40},"2016-03-10",{"date":70,"type":21},"2030-04-30",{"name":72,"class":73},"Washington University School of Medicine","OTHER",{"id":75,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":80,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":87,"locationsCount":48},"100641631",{"count":20,"type":21},[24],"Background:\n\nInjury or diseases of the heart and lung can sometimes cause scar tissue (fibrosis) to build up in those organs. Current imaging scans can see this scar tissue once it has formed, but researchers want to find a way to detect the fibrosis in its earliest stages, while there might still be time to prevent serious damage. A new tracer (a radioactive substance injected during imaging scans) may be able to help.\n\nObjective:\n\nTo test a new tracer (18F-FAPI-74) during imaging scans in people with heart or lung disease.\n\nEligibility:\n\nPeople aged 18 years and older with lung or heart disease that may cause scarring in those organs.\n\nDesign:\n\nParticipants will have 6 clinic visits over 2 years.\n\nParticipants will be screened: They will have blood tests and tests of their heart and lung function. Those with heart disease will have a magnetic resonance imaging (MRI) scan of the heart.\n\nThe study tracer will be used with positron emission tomography (PET)\u002Fcomputed tomography (CT) scans. The study tracer will be injected into a vein in the arm. Participants will lie on a padded bed that slides through a donut-shaped machine.\n\nParticipants will have scans with the study tracer 2 times, 8 to 12 months apart. They will also have standard CT scans and blood tests during these visits. They will also have blood tests at 3 and 6 months between these visits.\n\nParticipants will have a follow-up visit after 18 to 24 months. The study scans, MRI and standard CT scans, and lung function tests may be repeated.",[27,28,29,30,31,32],[34,35],"2026-07-01",{"date":83,"type":40},"2026-07-02",{"date":85,"type":21},"2026-07-07",{"date":44,"type":21},{"name":46,"class":47},{"id":89,"slug":4,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":94,"targetDuration":96,"studyType":58,"phases":4,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":99,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":106},"100612643","NCT07256249","Real-life Registry in Patients With Coronary Artery Disease Treated With the SELUTION Sirolimus-eluting Balloon. Selution Iberia Registry","SELUTION","Inclusion Criteria:\n\n* Patients with age ≥18 years and;\n* Patients with coronary artery disease in whom, at the operator's discretion, treatment of a lesion in a native vessel, coronary graft or coronary restenosis is decided using the Selution SLRTM device;\n* Patient who has been informed of the characteristics of the study and has provided written informed consent.\n\nExclusion Criteria:\n\n* Express refusal of the patient to participate in the study\n* Life expectancy of the patient of less than 12 months",{"count":95,"type":21},960,"12 Months","Selution Iberia registry is a post-market clinical follow-up, prospective, multicenter, international, longitudinal, observational study without a control group of consecutive unselected \"real-world\" patients with coronary artery disease in whom it was decided to use the SELUTION SLRTM device in the treatment of primary native lesions and ISR (in-stent restenosis) in all settings, in order to evaluate its effectiveness and safety.\n\nThe primary objective is to evaluate the effectiveness and safety of the Sirolimus-eluting balloon SELUTION SLRTM based strategy in the treatment of native coronary artery stenosis and in-stent restenosis. The primary endpoint will be the incidence of major adverse cardiovascular events at 12 months, including death, non-fatal myocardial infarction or target lesion revascularization for ischemia, in an unselected \"real-world\" patient setting. Both Device Oriented Composite Endpoint (Cardiovascular death, device failure-related myocardial infarction or device failure-related ischaemia) and Patient Oriented Composite Endpoint (all cause death, any stroke, any myocardial infarction or any revascularization) will be detailed.",[32],{"date":83,"type":40},{"date":101,"type":40},"2025-12-11",{"date":103,"type":21},"2027-01-01",{"name":105,"class":73},"Fundación EPIC",10,{"id":108,"slug":4,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":54,"sex":16,"minAge":112,"maxAge":18,"enrollmentInfo":113,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":120,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":48},"100558565","NCT06552767","Thrombosis and Inflammation in Vessels Initiative (TIVI)","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Age \\>= 5 years at the time of consent\n* Ability of subject or Legally Authorized Representative (LAR) as applicable to understand and the willingness to sign a written informed consent document\n\nIn addition, the following cohort-specific inclusion criteria apply:\n\nAffected Subjects:\n\n-Known or possible thrombotic, immune, or vascular disorder after review of the subject s medical records and\u002For discussion of medical history\n\nRelatives of Affected Subjects:\n\n-Being a relative of an affected subject\n\nUnrelated Healthy Controls:\n\n-In good general health as evidenced by medical history\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n-Any condition that in the opinion of the Investigator would warrant exclusion\n\nUnrelated Healthy Controls:\n\n* Unrelated healthy volunteers who decline to have blood drawn and\u002For tissue studies or who do not consent to have samples stored for future research\n* Cognitively impaired individuals","5 Years",{"count":114,"type":21},1000,"Background:\n\nDiseases related to the immune system, blood clots, and blood vessels can affect every part of the body. These diseases are now known to be interrelated: People who have strokes, blood clots in their legs, or autoimmune disease, for example, are at greater risk of complications in the heart, brain, and other organs. Researchers want to learn more about how these diseases start, how they change over time, and how they affect different organs.\n\nObjective:\n\nTo learn more about how inflammation and diseases of the blood vessels start and how they change over time.\n\nEligibility:\n\nPeople aged 5 years and older with a disease related to blood clots, the immune system, or blood vessels. Healthy relatives of people with these diseases and unrelated healthy volunteers are also needed.\n\nDesign:\n\nParticipants will have a baseline visit: They will provide a medical history, physical exam and blood test. All other tests and procedures are optional; these may be spread over more than 1 day:\n\nTests of heart and lung function.\n\nFill in a family tree form.\n\nImaging scans\n\nTreadmill or bike stress tests and a 6-minute walk test.\n\nTests of blood pressure and the flow of blood through vessels.\n\nPhotos of the face and body.\n\nEye exams, with photos taken of the retina.\n\nSaliva and urine samples.\n\nBiopsies (tissues samples) of the skin and fat.\n\nTests of thinking and mental function.\n\nEvaluations by other medical specialists.\n\nParticipants may opt to return for repeat testing for up to 90 months (7.5 years).\n\nSome visits may be done by telehealth.",[32,117],"Vascular Diseases",[119],"Vascular",{"date":83,"type":40},{"date":122,"type":40},"2024-11-22",{"date":124,"type":21},"2034-01-30",{"name":46,"class":47},{"id":127,"slug":4,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":133,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":139,"conditions":140,"keywords":141,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":153},"100568058","NCT06676280","ASpirin Use and stAtin Strategy for Primary Prevention in Severe Coronary Calcium Score on Computed Tomography","an Investigator-initiated, Multicenter, Open-label, 2-by-2 Factorial, and Randomized Trial to Evaluate the Role of Aspirin and High-intensity Statin Therapy, Respectively, in Individuals With Severe Coronary Calcification (Coronary Calcium Score ≥300) to Prevent Atherosclerotic Cardiovascular Disease (ASCVD) Events With Severe Coronary Calcification (CAC ≥300)","ASA-3C","Inclusion Criteria:\n\n1. The subject must be aged between 40 and 75 years.\n2. Patients who have coronary artery calcium score ≥300 Agatston Unit on coronary calcium computed tomography.\n3. Patients who have 1 or more CVD risk factors in below;\n\n   * dyslipidemia or,\n   * diabetes or,\n   * hypertension or,\n   * family history of CVD or,\n   * smoking\n4. Patients agree to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board\u002FEthical Committee of the respective clinical site.\n\nExclusion Criteria:\n\n1. Individuals who have symptomatic coronary artery disease or heart failure.\n2. Patients who have documented clinical Atherosclerotic Cardiovascular Disease: previous myocardial infarction, acute coronary syndrome, stable angina, coronary revascularization and other arterial revascularization procedures, stroke and Transient ischaemic attack (TIA), \\>50% carotid stenosis or previous carotid endarterectomy or stenting, aortic aneurysm and peripheral artery disease.\n3. Patients who have evidence of myocardial ischemia on non-invasive stress test including stress single photon emission CT myocardial perfusion imaging (SPECT MPI), cardiovascular magnetic resonance (CMR) imaging, stress echocardiography, or treadmill test, or on invasive stress test including Fractional flow reserve (FFR) \\\u003C 0.80 on invasive coronary angiography (diameter stenosis\\>50% without objective evidence of ischemia could be enrolled).\n4. Patients at high risk of bleeding: gastrointestinal hemorrhage or peptic ulcer within the previous 6 months; active hepatic disease such as cirrhosis or active hepatitis; use of warfarin, or other anticoagulant therapy; or has a history of aspirin allergy.\n5. Patients with atrial fibrillation and flutter.\n6. Patients with severe left ventricular dysfunction (ejection fraction ≤30%) or severe valvular heart disease who experience dyspnea on exertion (The NYHA (New York Heart Association) Functional Classification III-IV).\n7. History of allergy or severe adverse reaction to aspirin or statin or ezetimibe.\n8. History of myositis or myopathy with active disease in the 180 days prior to study entry.\n9. Patients with active liver disease or persistent unexplained serum transaminase elevation.\n10. Patients who have significantly abnormal findings which identified violation for safety by investigator on physical examination, blood test and electrocardiogram.\n11. History of alcohol or drug abuse.\n12. Concurrent medical condition with a life expectancy of less than 1 years.\n13. Pregnant and\u002For lactating women.\n14. Patient was unable to provide written informed consent or participate in log-term follow up.","40 Years","75 Years",{"count":136,"type":21},5000,[138],"PHASE4","The primary objective of the ASA-3C trial is to evaluate the role of aspirin and high-intensity statin therapy, respectively, in individuals with severe coronary calcification (coronary calcium score ≥300) to prevent atherosclerotic cardiovascular disease (ASCVD) events with severe coronary calcification (CAC ≥300).",[32],[142,143,144],"atherosclerotic cardiovascular disease","aspirin","high-intensity statin","2026-06-30",{"date":81,"type":40},{"date":148,"type":40},"2025-07-24",{"date":150,"type":21},"2035-12-31",{"name":152,"class":73},"Jung-min Ahn",32,{"id":155,"slug":4,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":22,"phases":163,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":179},"100601857","NCT07115953","Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension","Sub-study of SPYRAL AFFIRM: Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT)","SWYFT","Inclusion Criteria:\n\n1. Individual is diagnosed with hypertension and has a baseline office systolic blood pressure ≥140 mmHg\n2. Individual has a baseline office diastolic blood pressure ≥ 90 mmHg\n3. Individual has an average systolic baseline home blood pressure ≥135 mmHg (with ≥7 days of valid pre-procedure measurements)\n4. Individual has a valid 24-hour Ambulatory Blood Pressure Measurement at baseline\n\nExclusion Criteria:\n\n1. Individual lacks appropriate renal artery anatomy\n2. Individual has undergone prior renal denervation\n3. Individual has a documented condition that would prohibit or interfere with ability to obtain an accurate blood pressure measurement\n4. Individual requires chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea\n5. Individual has an estimated glomerular filtration rate (eGFR) of \\\u003C45 mL\u002Fmin\u002F1.73m2\n6. Individual has one or more episode(s) of orthostatic hypotension\n7. Individual is pregnant, nursing or planning to become pregnant\n8. Individual has documented primary pulmonary hypertension\n9. Individual has documented type 1 diabetes mellitus or poorly-controlled type 2 diabetes mellitus with glycosylated hemoglobin greater than 8.0%",{"count":162,"type":21},130,[164],"NA","The purpose of the SPYRAL SWYFT sub-study is to evaluate whether renal denervation with the Symplicity Spyral system performed in the main and first order branch renal arteries yields a shorter procedure time and is as effective in reducing blood pressure than the procedural approach used in the SPYRAL HTN-ON MED and SPYRAL PIVOTAL - SPYRAL HTN-OFF MED clinical studies in an uncontrolled hypertensive population.",[167,117,32,168,169],"Hypertension","Chronic Kidney Diseases","Diabetes Mellitus","2026-06-29",{"date":145,"type":40},{"date":173,"type":40},"2025-09-22",{"date":175,"type":21},"2029-12-31",{"name":177,"class":178},"Medtronic Vascular","INDUSTRY",21,{"id":181,"slug":4,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":54,"sex":16,"minAge":55,"maxAge":134,"enrollmentInfo":187,"targetDuration":4,"studyType":22,"phases":189,"briefSummary":190,"conditions":191,"keywords":195,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":48},"100639438","NCT07614659","Uppsala Self-Screening of Cardiovascular Health","Uppsala Self-Screening of Cardiovascular Health: A Randomized Controlled Trial of Home-Based Multimodal Cardiovascular Screening Versus Usual Care in Middle-Aged and Older Adults","U-SCREEN","Inclusion Criteria:\n\n* Resident in Region Uppsala, Sweden\n* Turning 50, 55, 60, 65, 70 or 75 years during recruitment period\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Protected identity",{"count":188,"type":21},45000,[164],"U-SCREEN is a randomized controlled trial evaluating whether systematic home-based multimodal screening for cardiovascular risk conditions, offered to residents in Region Uppsala turning 50, 55, 60, 65, 70 or 75 years of age, can identify clinically actionable cardiovascular risk factors more effectively than usual care. Participants randomized to the screening arm receive a home blood pressure measurement device, a dried blood spot sampling kit (for ApoB, HbA1c and creatinine), and a digital questionnaire. The control arm receives usual care. Recruitment runs 2024-2027 with a target identification of 10,000 cardiovascular risk conditions.",[32,167,192,169,193,194],"Dyslipidemias","Atrial Fibrillation","Chronic Kidney Disease",[196,197,198,199,200,201,202],"Population screening","Cardiovascular prevention","Home blood pressure monitoring","Dried blood spot","Digital health","Pragmatic trial","Register-based randomized controlled trial","2026-06-26",{"date":145,"type":40},{"date":206,"type":40},"2025-02-01",{"date":208,"type":21},"2037-12",{"name":210,"class":73},"Johan Sundström",{"id":212,"slug":4,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":16,"minAge":218,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":22,"phases":222,"briefSummary":223,"conditions":224,"keywords":227,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":238},"100641216","NCT07613294","A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Lepodisiran to Investigate the Effect on Coronary Plaque in Adults With Elevated Lp(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event","ACCLAIM-CTA","Inclusion Criteria:\n\n* Have an Lp(a) ≥175 nmol\u002FL\n* Have established cardiovascular (CV) disease or are at risk for a first CV event\n* Have angiographic evidence of coronary artery disease on screening CCTA\n* If taking lipid-lowering medications, inclusive of statins or prescription strength niacin and PCSK9 inhibitors, these should be stable for 8 weeks\n\nExclusion Criteria:\n\n* Have had a major CV event less than 60 days before measurement of the Lp(a) level used for eligibility or uncontrolled high blood pressure at screening\n* Have moderate to severe renal dysfunction\n* Have severe heart failure\n* Have a history of coronary artery bypass graft surgery (CABG)\n* Have a planned coronary angiography, percutaneous coronary intervention (PCI), coronary artery bypass graft, or valvular intervention\n* Have had a procedure to remove lipoproteins from the blood or received therapy specifically targeting Lp(a)\n* Are unable to safely undergo CCTA due to medication intolerance, contrast allergies, or anatomical\u002Ftechnical factors","45 Years","80 Years",{"count":221,"type":21},252,[24],"Lipoprotein(a), also known as Lp(a), is a protein that carries cholesterol and proteins in your blood. People with high Lp(a) have a higher risk for heart disease. The main purpose of the study is to investigate how lepodisiran, compared to a placebo, affects the amount and type of plaque in the heart's vessels using an imaging technology known as Coronary Computed Tomography Angiography (CCTA) in adults who have high levels of Lp(a).\n\nParticipation will last about 120 weeks.",[225,32,226],"Atherosclerosis","Lipoprotein(a)",[228,229],"CCTA","Coronary plaque burden","2026-06-25",{"date":170,"type":40},{"date":233,"type":40},"2026-06-02",{"date":235,"type":21},"2029-04",{"name":237,"class":178},"Eli Lilly and Company",59,{"id":240,"slug":4,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":16,"minAge":133,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":22,"phases":248,"briefSummary":249,"conditions":250,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":251,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":258},"100586007","NCT06909773","The Prevalence of COPD in Patients With Cardiovascular Disease and the Benefit of Cardiopulmonary Co-management","The Prevalence of COPD in Patients With Cardiovascular Disease and the Benefit of Cardiopulmonary Co-management -A Multi-center, Prospective, Interventional Study (PRECEDE)","PRECEDE","Inclusion Criteria:\n\n1. Give signed written informed consent to participate.\n2. At least 40 years of age at baseline visit.\n3. Previous or newly diagnosed by at least one of the 3 types of CVD which are,\n\n   * Coronary heart disease ( CHD )\n   * Atrial fibrillation (AF )\n   * Chronic heart failure ( CHF )\n4. Participants can undergo spirometry testing and does not have the following serious diseases or disease states：\n\n   * Shock within the last 3 months\n   * Mycardial infarction, stroke or unstable angina within last 1 month\n   * Currently suffering from severe HF or severe arrhythmia. Severe HF refers to the need for intravenous administration of vasoactive drugs and diuretics; severe arrhythmia refers to arrhythmias that cause hemodynamic instability, such as ventricular fibrillation and ventricular tachycardia\n   * Severe hemoptysis or active gastrointestinal bleeding within last 1 month\n   * Patients with seizures requiring medication\n   * Patients with hypertensive crisis or uncontrolled hypertension \\[systolic blood pressure \\> 200 mmHg, diastolic blood pressure \\> 100 mmHg (1 mmHg = 0.133 kPa)\\]\n   * Patients with active respiratory infectious diseases or infectious diseases, such as open pulmonary tuberculosis, influenza, new coronavirus infection, and acute pneumonia\n   * Patients with aortic or cerebral aneurysms\n   * Pneumothorax and pneumothorax healing within last 1 month\n   * Patients with severe hyperthyroidism\n   * Patients who have recently had eye, ear, cranial or thoracic or abdominal surgery Note: If the patient can cooperate by completing a single, effective forced exhalation (≥6 seconds), then spirometry testing can be performed.\n5. Subjects have the cognitive ability to conduct questionnaires after e valuated by investigators.\n\nExclusion Criteria:\n\n1. Significant diseases or conditions, which, in the opinion of the investigator, may put the participant at risk because of participation in the study or may influence either the results of the study or the participant's ability to participate in the study.\n2. Women who are pregnant or lactating or are planning to become pregnant, or women of childbearing potential who are not using an acceptable method of contraception.\n3. Participant who are not able to provide written informed consent.\n4. Treatment with investigational study drug or device in another clinical study within the last 30 days or five half lives prior to baseline visit , whichever is longer.",{"count":247,"type":21},3000,[164],"This is a multi-center, prospective, and interventional study conducted in 3 types of cardiovascular diseases (CVD) participants , including 3 cohorts which are patients with newly or previously diagnosed coronary heart disease ( CHD), atrial fibrillation ( AF) and chronic heart failure (CHF).",[32],{"date":203,"type":40},{"date":253,"type":40},"2025-11-28",{"date":255,"type":21},"2026-12-31",{"name":257,"class":178},"AstraZeneca",85,{"id":260,"slug":4,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":134,"enrollmentInfo":266,"targetDuration":4,"studyType":22,"phases":267,"briefSummary":268,"conditions":269,"keywords":278,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":48},"100644654","NCT07674511","Impact of Transcutaneous Spinal Stimulation on Blood Pressure and Orthostasis in Spinal Cord Injury","Impact of Transcutaneous Spinal Stimulation on Blood Pressure and Orthostasis in Spinal Cord Injury: Short and Long-Term Effects","(SCI)","Inclusion Criteria:\n\n* Individuals with a SCI ≥ 1 year after injury\n* Injury level ≥ T6 (thoracic level)\n* AIS grade A-C\n* Cardiovascular dysfunction characterized by one or more of the following:\n\n  1. Persistent hypotension (SBP \\\u003C 90mmHg)\n  2. Orthostatic hypotension (OH, a drop of 20\u002F10 mmHg in SBP\u002FDBP within 5 minutes of standing\u002Fupright positioning).\n\nAdditionally, experiencing orthostatic symptoms in daily life and\u002For requiring medication to manage OH.\n\nExclusion Criteria:\n\n* Current illness (e.g., infection, a pressure injury that might interfere with the intervention)\n* Ventilator-dependent\n* History of implanted brain\u002Fspine\u002Fnerve stimulators\n* Cardiac pacemaker\u002Fdefibrillator or intra-cardiac lines\n* Significant coronary artery or cardiac conduction disease, a recent history of myocardial infarction\n* History of seizures\n* pregnancy\n* Insufficient mental capacity to understand and independently provide consent\n* Deemed unsuitable by the study physician",{"count":106,"type":21},[164],"The purpose of this study is to learn whether stimulation applied to the spinal cord through the skin (called transcutaneous spinal stimulation) can help control blood pressure in people with a spinal cord injury.\n\nThe main questions this study attempts to solve:\n\n1. What are the immediate effects of spinal cord transcutaneous stimulation on BP?\n2. Does stimulation produce lasting improvements in BP regulation and subsequently, daily function?",[270,271,272,273,32,274,275,276,277],"Spinal Cord Injuries","Hypotension","Orthostatic Hypotension","Spinal Cord Diseases","Trauma, Nervous System","Central Nervous System Disease","Nervous System Diseases","Blood Pressure",[279,280,281,282,283],"transcutaneous spinal cord stimulation","spinal stimulations","orthostatic hypotension","blood pressure","neuromodulation","2026-06-24",{"date":170,"type":40},{"date":287,"type":21},"2026-09",{"date":289,"type":21},"2028-12",{"name":291,"class":73},"Kessler Foundation",{"id":293,"slug":4,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":11,"sex":298,"minAge":17,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":22,"phases":301,"briefSummary":302,"conditions":303,"keywords":305,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":307,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":314},"100531670","NCT06202820","CV CARE: CardioVascular Care in PC Patients","CV CARE: CardioVascular Care of Androgen Related Effects in Prostate Cancer Patients","Inclusion Criteria:\n\n* Participants must have a histologic diagnosis of prostate adenocarcinoma. Participants with any stage of prostate cancer are eligible, as long as treatment with at least 24 weeks of ADT is recommended by their treating physician.\n* Participants must have been prescribed a plan for treatment with at least 24 weeks of ADT, and can have received up to 12 weeks of ADT therapy.\n* Participants must be willing to participate in two CV CARE visits at weeks 12 and 24 after ADT initiation.\n* Participants must be willing to have their follow up visits for ADT management at DFCI Longwood site.\n* Participants must be willing to undergo lab and blood pressure assessments, which can include local labs and home blood pressure checks if they wish to do virtual visits for follow up care.\n* Participants can have pre-existing CVD and\u002For CV risk factors, but this is not a requirement for inclusion.\n* Participants receiving combination treatment with an androgen receptor signaling inhibitory, some examples being (abiraterone acetate, enzalutamide, darolutamide, apalutamide, or bicalutamide), immunotherapy (pembrolizumab), or PARP inhibitor (olaparib, rucaparib) are eligible.\n* Age ≥18 years.\n* Life expectancy of greater than 6 months.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* History of major adverse cardiac event, including myocardial infarction, new congestive heart failure (CHF) or CHF exacerbation, or stroke, within the past 24 weeks due to complicated comorbidities that necessitate close collaboration between the participant and their cardiologist.\n* Participants who have already been on ADT therapy for more than 12 weeks are ineligible due to their treatment cycle being incompatible with the quality improvement initiative's trial design. ADT therapy is defined as either a GnRH agonist or antagonist.\n* Participants receiving combination treatment with ADT and chemotherapy (docetaxel, cabazitaxel, carboplatin), radioligand therapy (radium-223, 177PSMA-lutetium-617), or treatment on a clinical trial are not eligible due to potential for more intensive symptom management that may be required for optimal support of their cancer-directed treatment.\n* Participants actively included in therapeutic clinical trials are not eligible due to their greater time constraints.","MALE",{"count":300,"type":21},180,[164],"This research is being done to test a program to assess and manage reversible cardiovascular (CV) risk factors in participants with prostate cancer starting androgen deprivation therapy (ADT), with the goal of integrating a standardized method into Dana-Farber Cancer Institute clinics for all such participants.\n\nThe name of the intervention used in this research study is:\n\nCV Care (cardiovascular risk assessment and management program)",[304,32],"Prostate Cancer",[304,32,306],"Cardiovascular Risk",{"date":170,"type":40},{"date":309,"type":40},"2024-01-18",{"date":311,"type":21},"2027-06-30",{"name":313,"class":73},"Dana-Farber Cancer Institute",2,{"id":316,"slug":4,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":4,"eligibilityCriteria":320,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":321,"targetDuration":4,"studyType":22,"phases":323,"briefSummary":324,"conditions":325,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":335},"100597898","NCT07064473","EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease","EASi-PROTKT™ - A Phase III Double-blind, Randomised, Parallel-group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral Vicadrostat (BI 690517) and Empagliflozin Compared With Placebo and Empagliflozin in Participants With Type 2 Diabetes, Hypertension and Established Cardiovascular Disease","Inclusion Criteria :\n\n* At least 18 years old at time of consent\n* Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial\n* Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per ICH M3 (R2).\n* Participants with medical history of hypertension and on active pharmacological treatment\n* Participants with medical history of type 2 diabetes mellitus (T2DM) and on active pharmacological treatment\n* Established cardiovascular (CV) disease and on active pharmacological treatment\n* At least one additional risk factor for developing heart failure (HF)\n\nExclusion Criteria:\n\n* History of HF or hospitalization for HF or treatment of HF\n* Atrial fibrillation or Atrial flutter with a resting heart rate \\>110 beats per minute (bpm) documented by echocardiogram (ECG) at Visit 1 (screening)\n* Advanced untreated conduction disease or untreated clinically relevant ventricular arrhythmia at Visit 1 (screening)\n* Treatment with an Mineralocorticoid receptor antagonist (MRA)\n* Treatment with amiloride or other potassium-sparing diuretic\n* Receiving the following treatments at Visit 1 (screening) or requiring such treatment before Visit 2 (randomisation), or planned during the trial:\n\n  * A direct renin inhibitor (e.g. aliskiren)\n  * More than one Angiotensin-converting enzyme inhibitor (ACEi) and\u002For Angiotensin receptor blocker (ARB) (including Angiotensin receptor-neprilysin inhibitor (ARNi)) used simultaneously\n  * Other aldosterone synthase inhibitors (e.g. baxdrostat)\n  * Systemic mineralocorticoid replacement therapy (e.g. fludrocortisone) Further exclusion criteria apply.",{"count":322,"type":21},11800,[24],"This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure. The purpose of this study is to find out if a medicine called vicadrostat, when taken with empagliflozin, helps reduce cardiovascular risk in people with these conditions. The study will compare this combination to a placebo version of vicadrostat with empagliflozin.\n\nParticipants are put into 2 groups randomly, which means by chance. One group takes vicadrostat and empagliflozin tablets, and the other group takes placebo tablets with empagliflozin. Placebo tablets look like vicadrostat tablets but do not contain any medicine.\n\nParticipants take a tablet once per day for 2 and a half years and up to 4 years and 3 months. All participants also continue their medication for type 2 diabetes, high blood pressure, and cardiovascular disease. Participants have an equal chance of receiving the study medicine or placebo.\n\nParticipants are in the study for up to 4 years and 3 months. During this time, they visit the study site regularly. During these visits, doctors collect information about participants' health and take blood samples. The doctors document when participants experience cardiovascular events. The doctors also regularly check participants' health and take note of any unwanted effects.",[326,167,32],"Diabetes Mellitus, Type 2","2026-06-23",{"date":284,"type":40},{"date":330,"type":40},"2025-07-22",{"date":332,"type":21},"2029-12-21",{"name":334,"class":178},"Boehringer Ingelheim",1155,{"id":337,"slug":4,"hasResults":11,"nctId":338,"briefTitle":339,"officialTitle":339,"acronym":4,"eligibilityCriteria":340,"healthyVolunteers":54,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":341,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":343,"conditions":344,"keywords":346,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":348,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":48},"100559153","NCT06560424","Cardiovascular and Metabolic Sciences Biorepository","Inclusion Criteria:\n\n* Willing and able to sign the informed consent document\n\nExclusion Criteria:\n\n* Chronic anemia (hemoglobin consistently \\\u003C9 g\u002FL)",{"count":342,"type":21},10000,"The purpose of the Cardiovascular and Metabolic Sciences Biorepository is to collect and store information and biospecimens (blood, urine, stool, and heart tissue) from patients with and without cardiovascular and metabolic diseases to create a readily available biorepository of samples and related medical health information to expedite future research into the causes and consequences of cardiovascular and metabolic diseases.",[32,345],"Metabolic Disease",[347],"Biorepository",{"date":230,"type":40},{"date":350,"type":40},"2024-09-18",{"date":352,"type":21},"2050-12-31",{"name":354,"class":73},"The Cleveland Clinic",{"id":356,"slug":4,"hasResults":11,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":360,"eligibilityCriteria":361,"healthyVolunteers":11,"sex":16,"minAge":133,"maxAge":362,"enrollmentInfo":363,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":365,"conditions":366,"keywords":367,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":48},"100624429","NCT07409519","Nutritional Screening in Cardiovascular Disease","Nutritional Screening in Patients With Cardiovascular Disease","NS","Inclusion Criteria:\n\n• No pre-specified inclusion criteria to ensure we recruit a representative group of patients.\n\nExclusion Criteria:\n\n* All patients without proficiency in English that allows completion of questionnaires\n* Unable to provide written consent","85 Years",{"count":364,"type":21},250,"This is a nutritional screening and assessment study conducted prior to heart surgery. The nutritional status of patients will be assessed by a series of questionnaires, blood\u002Furine biomarkers and measurement of grip strength and body composition. The investigators will then evaluate of any of the assessments are linked with clinical outcomes following surgery. For example, how long do patients stop in the intensive care unit (ICU), in hospital and how many complications patients experience.\n\nThe investigators hope to use this important clinical data to understand how medical staff can identify a poor nutritional status and which patients may need nutritional support prior to surgery.",[32],[368,369,370,371],"Nutrition","Screening","Cardiac surgery","Clincial outcomes","2026-06-22",{"date":327,"type":40},{"date":375,"type":40},"2025-08-20",{"date":377,"type":21},"2027-01-10",{"name":379,"class":380},"Hull University Teaching Hospitals NHS Trust","OTHER_GOV",{"id":382,"slug":4,"hasResults":11,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":386,"eligibilityCriteria":387,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":219,"enrollmentInfo":388,"targetDuration":4,"studyType":22,"phases":390,"briefSummary":391,"conditions":392,"keywords":393,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":402,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":408},"100585805","NCT06907147","SPYRAL GEMINI Pilot Study","Global Pilot Study of rEnal and Hepatic coMbINed denervatIon in Subjects With Uncontrolled Hypertension With and Without High Cardiovascular Risk","SPYRAL GEMINI","Inclusion Criteria:\n\nAll Subjects (both cohorts):\n\n1. ≥18 and ≤80 years of age.\n2. Diagnosed with HTN and has a baseline office SBP ≥150 mmHg and \\\u003C180 mmHg and an office DBP ≥ 90 mmHg.\n3. 24-hour average SBP ≥140 mmHg and \\\u003C170 mmHg measured by ABPM at Baseline.\n\nExclusion Criteria:\n\n1. Individual lacks appropriate renal artery OR common hepatic artery anatomy.\n2. Prior renal or hepatic denervation.\n3. History of NYHA Class III or IV heart failure within 6 months of screening visit.\n4. Stroke or transient ischemic attack (TIA) within 6 months of screening visit or any history of stroke leading to permanent disability.\n5. Documented Type 1 diabetes or use of insulin within 6 months.\n6. Secondary cause of hypertension.\n7. Documented condition that would prohibit or interfere with ability to obtain an accurate blood pressure measurement.\n8. Estimated glomerular filtration rate (eGFR) of \\\u003C40\n9. Pregnant, nursing or planning to become pregnant during the study.\n10. Primary pulmonary arterial hypertension.\n11. History or evidence of active \u002F suspected chronic liver or biliary disease.\n12. Current or chronic pancreatitis.",{"count":389,"type":21},175,[164],"The purpose of the SPYRAL GEMINI Pilot Study is to evaluate that multi-organ denervation with the Gemini System is safe and provide evidence of blood pressure reduction when studied in an uncontrolled hypertensive population with and without high cardiovascular risk.",[167,117,32,168,169],[394,395,396,397,398,167,32,117,399,400,401],"Renal Insufficiency","Chronic Disease","Disease Attributes","Pathologic Processes","Kidney Diseases","Denervation","Renal Denervation","Hepatic Denervation",{"date":284,"type":40},{"date":404,"type":40},"2025-05-01",{"date":406,"type":21},"2029-12-22",{"name":177,"class":178},18,{"id":410,"slug":4,"hasResults":11,"nctId":411,"briefTitle":412,"officialTitle":412,"acronym":4,"eligibilityCriteria":413,"healthyVolunteers":54,"sex":414,"minAge":17,"maxAge":4,"enrollmentInfo":415,"targetDuration":4,"studyType":22,"phases":417,"briefSummary":418,"conditions":419,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":424,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":48},"100502797","NCT05826925","Optimizing Cardiovascular Preventive Care for Women Following Hypertensive Disorders of Pregnancy","Inclusion Criteria:\n\n* Delivered a pregnancy complicated by a hypertensive disorder of pregnancy at the University of Utah during the current hospital admission\n* Ability to speak and read English or Spanish\n* Written informed consent obtained\n\nExclusion Criteria:\n\n* Cardiovascular disease diagnosis (history of peripheral artery disease, stroke, or myocardial infarction)\n* Impairment of cognitive function or vision that prohibits communication and\u002For reading the decision aid.","FEMALE",{"count":416,"type":21},30,[164],"Cardiovascular disease is the leading cause of death among women in the United States, and women with hypertensive disorders of pregnancy have a 2-fold higher risk for cardiovascular disease later in life compared to women with uncomplicated pregnancies. This research investigates a patient-centered intervention during the postpartum period to promote engagement in cardiovascular preventive care.",[420,421,422,32,423],"Hypertension, Pregnancy Induced","Hypertension Complicating Pregnancy","Preeclampsia","Patient Engagement",{"date":327,"type":40},{"date":426,"type":21},"2026-07-15",{"date":428,"type":21},"2027-08",{"name":430,"class":73},"University of Utah",{"id":432,"slug":4,"hasResults":11,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":436,"eligibilityCriteria":437,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":438,"enrollmentInfo":439,"targetDuration":4,"studyType":22,"phases":441,"briefSummary":442,"conditions":443,"keywords":445,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":450,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":454,"locationsCount":48},"100361242","NCT03983603","Plant Stanol Esters and Preventing Asthma Symptoms","The Effects of Long-term Daily Plant Stanol Ester Intake on Clinical Symptoms in Individuals With Allergic Asthma: an Exploratory Double-blind Randomized Controlled Trial","PLANTASTIC","Inclusion Criteria:\n\n* Diagnosed with allergic asthma (GINA step 1-4) which is in a stable phase at the moment of inclusion (defined as no changes in asthma control and lung function in (at least) the past three months)\n* Have been treated with prescribed asthma medication for at least one year\n* Aged 18-70 years old\n* BMI between 20 and 35 kg\u002Fm2\n* Willing to abstain from products containing plant sterols or stanols one month prior to the study (products with a cholesterol lowering claim of Becel ProActiv, Benecol, Danacol, store brands)\n* Willing to abstain from products containing plant sterols or stanols during the study (products with a cholesterol lowering claim of Becel ProActiv, Benecol, Danacol, store brands)\n* Willing to keep the intake of fish oil supplements constant\n\nExclusion Criteria:\n\n* Currently smoking or quitted smoking in the past year, with a maximum of 10 packyears as smoking history (packyears = packs per day \\* years of smoking)\n* Allergy to an ingredient of the soft chews\n* Suffering from inflammatory diseases (for CVD, illness must be minimally 3 years ago and currently under control in order to participate in the study)\n* Fasting plasma glucose \\> 7.0 mmol\u002FL\n* Fasting serum TC \\> 8.0 mmol\u002FL\n* Having donated blood within one month prior to the start of the study, or planning to donate blood during the study\n* Pregnant women\n* Breastfeeding women","70 Years",{"count":440,"type":21},160,[164],"Plant stanols are known to lower low-density lipoprotein cholesterol. However, studies have suggested that these compounds also influence the immune system. Asthmatic responses are predominantly T helper (Th)2 cell dependent, while plant stanols were previously found to activate Th1 cells and shift the immune response away from the Th2 cell dominant asthmatic response. The question now is whether this also translates into a reduction of clinical symptoms in asthma patients.The primary objective of this study is to demonstrate clinical benefits of prolonged consumption of plant stanols (delivered via plant stanol esters) in asthma patients. The secondary objectives are to evaluate the mechanisms via which plant stanols modulate the immune system and to evaluate the effects of plant stanol ester consumption on cardiovascular (CVD) risk parameters.",[444,32],"Asthma, Allergic",[446,447,448,449],"Plant stanols","Asthma","Immune system","Metabolic health",{"date":230,"type":40},{"date":452,"type":40},"2019-04-29",{"date":287,"type":21},{"name":455,"class":73},"Maastricht University Medical Center",{"id":457,"slug":4,"hasResults":11,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":461,"eligibilityCriteria":462,"healthyVolunteers":54,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":463,"targetDuration":4,"studyType":22,"phases":465,"briefSummary":466,"conditions":467,"keywords":482,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":48},"100643981","NCT07669168","Health Ahead Comparative Effectiveness Study","Health Ahead: Sequential Comparative-Effectiveness Studies Toward Automated, Universally Deployable Preventive Health Screening","HACE","Inclusion Criteria:\n\n* Age 18 years or older\n* Willing and able to provide written informed consent, or enrollment with consent of a legally authorized representative\n* Willing to participate in longitudinal follow-up.\n\nExclusion Criteria:\n\n\\- Age under 18 years.",{"count":464,"type":21},1000000,[164],"The Health Ahead Comparative Effectiveness Study is a pragmatic, parallel-arm interventional platform that systematically compares successive changes to preventive health screening - each isolated as a single variable against current practice - on the path toward a fully automated screening system deployable in any environment, including the most isolated and resource-limited communities. Each comparison is evaluated with a common set of engagement, behavior-change, experience, cost, and longitudinal outcome measures, allowing results to accumulate on a consistent yardstick across the life of the platform.\n\nThe first comparison evaluates static versus interactive personalized health report delivery. Subsequent pre-planned comparisons, added by protocol amendment, evaluate mobile community versus fixed laboratory screening; and a hybrid medical-droid plus human-delivery model versus human-only screening. All participants are simultaneously enrolled in the 100-Year Human Aging Study and the Human Observatory Study, contributing individual longitudinal and population-level causal inference data through those protocols.",[468,469,470,471,472,473,474,32,475,476,477,478,479,480,481],"Health Services Accessibility","Rural Health","Medically Underserved Area","Preventive Health Services","Patient Participation","Health Behavior","Aging","Metabolic Syndrome","Cognitive Dysfunction","Frailty","Activities of Daily Living","Health Related Quality of Life","Health Equity","Telemedecine",[483,484,485,486,487,480,469,488,489,423,490,491,492,493,494,495,496,497,498,499,500,395,501,502],"Sequential Platform Trial","Interactive Health Report","Health Activation","Mobile Health Screening","Comparative Effectiveness","Medically Underserved","Preventive Medicine","Cardiopulmonary Exercise Testing","Body Composition","DEXA","Health Ahead Bus","Mobile Clinic","Automated Screening","Medical Droids","Biological Age","Healthspan","Longevity","Life Expectancy","Cost-Effectiveness","Health Services Research","2026-06-20",{"date":230,"type":40},{"date":506,"type":21},"2026-06-09",{"date":508,"type":21},"2099-12-31",{"name":510,"class":178},"William Brandenburg, MD",{"id":512,"slug":4,"hasResults":11,"nctId":513,"briefTitle":514,"officialTitle":515,"acronym":516,"eligibilityCriteria":517,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":518,"targetDuration":4,"studyType":22,"phases":520,"briefSummary":521,"conditions":522,"keywords":530,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":535,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":540,"locationsCount":48},"100644087","NCT07665827","Efficacy and Safety of Antihypertensive Treatment With Mobile Stroke Units in Ultra-Early Intracerebral Hemorrhage","Efficacy and Safety of Antihypertensive Treatment With Mobile Stroke Units in Ultra-Early Intracerebral Hemorrhage: A Multicenter, Prospective, Cluster-Randomized, Open-Label, Blinded-Endpoint Clinical Trial","MSU-ICH","Inclusion Criteria:\n\n1. History and physical\u002Fneurological examination consistent with acute stroke.\n2. Age ≥18 years;\n3. Time from symptom onset to enrollment \\\u003C3 hours (onset defined as last known normal).\n4. Systolic blood pressure ≥150 mmHg and ≤220 mmHg;\n5. Pre-stroke modified Rankin Scale (mRS) score ≤2;\n6. Informed consent obtained from the subject or a legally authorized representative.\n\nExclusion Criteria:\n\n1. Glasgow Coma Scale (GCS) score ≤5.\n2. Contraindications to intensive blood pressure lowering, including severe arterial stenosis or high-grade stenotic valvular heart disease.\n3. Malignant disease or other serious primary illness with a life expectancy of \\\u003C3 months.\n4. Current participation in another interventional randomized clinical trial.",{"count":519,"type":21},706,[164],"MSU-ICH is a prospective, multicenter, Week-wise-randomized, open-label, blinded-endpoint (PROBE) clinical trial comparing ultra-early prehospital blood pressure lowering delivered by a Mobile Stroke Unit (MSU) with standard Emergency Medical Services (EMS) in patients with spontaneous intracerebral hemorrhage.",[276,523,32,117,524,525,526,527,528,529],"Cerebrovascular Disorders","Hemorrhage","Intracranial Hemorrhages","Cerebral Hemorrhage","Cerebral Hemorrhage, Hypertensive","Stroke","Hemorrhagic Stroke, Intracerebral",[531,532,533],"intracerebral hemorrhage","mobile stroke units","Intensive blood pressure lowering","2026-06-18",{"date":284,"type":40},{"date":537,"type":21},"2026-06",{"date":539,"type":21},"2028-07",{"name":541,"class":73},"Xuanwu Hospital, Beijing",{"id":543,"slug":4,"hasResults":11,"nctId":544,"briefTitle":545,"officialTitle":545,"acronym":4,"eligibilityCriteria":546,"healthyVolunteers":54,"sex":16,"minAge":17,"maxAge":438,"enrollmentInfo":547,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":548,"conditions":549,"keywords":552,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":557,"lastUpdatePostDateStruct":558,"startDateStruct":559,"completionDateStruct":4,"leadSponsor":561,"locationsCount":48},"100054784","NCT00001853","Diabetes and Heart Disease Risk in Blacks","* IINCLUSION AND EXCLUSION CRITERIA\n\nCRITERIA FOR INCLUSION:\n\nEthnicity: Black\n\nThis is a study of adult African Americans and Blacks that were born in Africa but are now living in the United States. As African American people are multi-ethnic, we will in this initial investigation, study two different groups of African American. To enroll participants must self-identify as African Americans and be born in the United States, with American born parents or be born in Africa with African born parents. In both groups we will study sex differences in the role of obesity and TG levels on cardiovascular disease. In the future, we plan to expand the study to include other groups which self-identify as African Americans (i.e.AfroCarribeans and Hispanic blacks).\n\nOnly blacks are included in this study because the focus of this study is on gender differences in blacks in risk factors for CAD, specifically obesity, TG levels and TG related CAD risk factors. Unlike Caucasian women, premenopausal black women do not appear to be as protected from heart disease as a result of their gender. One model to study this apparent decrease in gender\n\nrelated cardioprotection in black women is to compare black men to black women. An alternative model would be to compare black women to Caucasian women. However, since the primary focus of this work is on gender differences rather than racial differences comparing black women to men is a superior model. Other racial groups do not share the loss of gender-related cardioprotection found in blacks, and have been excluded. Further the advantage of comparing black men and women is that this comparison provides a better control of dietary, cultural and genetic factors.\n\nAge: The age range of the participants will be between 18 and 70 years. As stated in the original protocol on page 14: Future investigations are planned which will involve similar comparisons between premenopausal and postmenopausal black women and between whites and blacks. To investigate risk for glucose intolerance, diabetes and cardiovascular risk factors, it is no longer sufficient to maintain the age range between 18 and 50 years. We need to expand to an age range with an increased prevalence of these risk factors.\n\nMedical History: To participate in the study subjects should identify themselves as healthy. This is important so the broadest possible sample of people will enroll. The fact that people are healthy will be confirmed by the history, physical and laboratory tests done as part of the screening visit. People with established coronary artery as evidenced by history of myocardial infarction, coronary artery bypass surgery or PTCA will be allowed to participate if they are not currently having angina.\n\nCRITERIA FOR EXCLUSION:\n\nBlack Ethnicity other than American or African.\n\nAs stated in the inclusion criteria black people are a multi-ethnic group. In this initial investigation we are focusing on African Americans who are American born and Africans living in the United States who are African born. In the future, we will expand the study to include other groups of blacks such as individuals of Afro-Caribbean and Hispanic blacks.\n\nMedications: People who take medications that are known to alter the parameters which are under investigation in this study will be excluded. People taking medications to treat hyperlipidemia will be included but analyses will be adjusted to take this into account. Subjects on thyroid hormone replacement will be included if their TSH is normal.\n\nDiabetes: Because diabetes affects insulin sensitivity and TG levels all people with diabetes even if the diabetes is controlled with diet alone will not be enrolled in the study.\n\nPregnant or Breastfeeding: Women who are pregnant, breastfeeding, or have an infant that is less than four months of age will be excluded. This is because the physiologic changes associated with pregnancy, breastfeeding or recent childbirth affect the parameters under study.\n\nMenstrual History: Now that postmenopausal women are included, menstrual history will be taken but women with irregular menses and hysterectomy will not be excluded. Women between the ages of 40 and 55 years will have FSH checked for proper characterization. Women 56 years of age and older will be assumed to be postmenopausal. However, women on any type of injectable hormonal contraception will be excluded because hormonal contraception affects both TG levels and glucose metabolism.",{"count":57,"type":21},"It is unknown if obesity contributes to the development of heart disease in African American men and women.\n\nThis study was created to determine whether there is a relationship between sex and body size and the incidence of heart disease in African American men and women. Researchers will attempt to associate obesity with the presence of heart disease risk factors. Risk factors that will be studied include; total body fat, body fat distribution, fat content of the blood (triglyceride concentration, low density lipoproteins \\[LDL\\], and high density lipoproteins \\[HDL\\]), how fast fat is removed from the blood, and how well insulin works in the body.\n\nScientific studies have shown that obesity and increased levels of fat content in the blood are important risk factors for heart disease in Caucasian women. However, similar studies in African American women have failed to show the same correlation. In fact, it appears that African American women in all three body weight groupings, nonobese, overweight, and obese experience high death rates due to heart disease. In addition, prior research has shown that obese African American men tend to have elevated levels of fat in the blood while African American women have normal blood fat levels. Therefore, if high levels of triglycerides (fat found in the blood) are not seen in non-diabetic obese African American women, it cannot be considered a risk factor in this population. This suggests that studies conducted on Caucasian women may not provide insight into heart disease risk factors in African American women.\n\nThe study will take 2000 healthy non-diabetic African American men and women (ages 18-70) and body mass index 3 subgroups; nonobese, overweight and obese. Diabetes undeniably increases the risk of heart disease. Therefore patients suffering from diabetes will not be included in the study. Candidates for the study will undergo a series of tests and examinations over 2 outpatient visits. Subjects will have body fat analyses, resting energy expenditure measurements, an EKG (electrocardiogram), and specific blood tests.\n\nResearchers believe this study will provide significant insight into the causes of obesity and heart disease in African Americans.",[32,550,551,167],"Diabetes","Obesity",[553,554,550,555,556],"Healthy Volunteers","Health Disparities","Cardiovascular Disease","Natural History","2026-06-17",{"date":534,"type":40},{"date":560,"type":40},"1998-10-21",{"name":562,"class":47},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",{"id":564,"slug":4,"hasResults":11,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":568,"eligibilityCriteria":569,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":219,"enrollmentInfo":570,"targetDuration":4,"studyType":22,"phases":572,"briefSummary":573,"conditions":574,"keywords":588,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":594,"startDateStruct":595,"completionDateStruct":597,"leadSponsor":599,"locationsCount":48},"100612800","NCT07258290","Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions","Safety and Clinical Performance of the Drug Eluting Resorbable Coronary Magnesium Scaffold System (Freesolve) in the Treatment of Subjects With de Novo Lesions in Native Coronary Arteries","BIOMAG-III","Clinical Inclusion Criteria:\n\n1. Subject is ≥ 18 years and ≤ 80 years of age\n2. Subject has provided written informed consent as approved by the Ethics Committee \u002F Institutional Review Board (IRB) of the respective clinical site prior to the study related procedures\n3. Subject is eligible for PCI according to the applicable guidelines\n4. Subject is an acceptable candidate for coronary artery bypass surgery\n5. Subjects with stable or unstable angina pectoris, documented silent ischemia\u002Fabnormal physiologic testing or hemodynamically stable non-ST elevation myocardial infarction (NSTEMI) patients without angiographic evidence of thrombus at target lesion\n\n   Note: STEMI patients may be eligible for the study for treatment of selected non-culprit lesions, if:\n   * Subject and target lesion(s) meet all inclusion and no exclusion criteria and consent occurs at least ≥ 72 hours after successful treatment of the culprit lesion(s) \\[lesion(s) causing the acute STEMI\\];\n   * Subject is hemodynamically stable with documented declining cardiac biomarkers;\n   * Target lesion(s) to be treated are not located in the culprit vessel(s) and are not culprit lesion(s)\n6. Subject is eligible for Dual Antiplatelet Therapy (DAPT) with aspirin plus either clopidogrel, prasugrel, ticagrelor or ticlopidine\n7. Documented left ventricular ejection fraction (LVEF) ≥ 30% within 6 months prior to or during the procedure (prior to randomization)\n8. Subject is willing and able to comply with protocol requirements, including completion of study visits for the duration of the study\n\nAngiographic Inclusion Criteria:\n\n1. Subjects with a maximum of two single de novo target lesions each in separate native coronary arteries\n2. Target vessel must have a reference diameter between 2.5-4.2 mm by operator visual estimation, which may be assisted by Quantitative Coronary Angiography (QCA) \u002F Intravascular Ultrasound (IVUS) \u002F Optical Coherence Tomography (OCT)\n3. Target lesion(s) must be ≤ 36 mm in length by operator visual estimation, which may be assisted by QCA \u002F IVUS \u002F OCT, (or \\\u003C 20 mm for target lesion(s) to be treated with a study device \\\u003C 3.0 mm in diameter) and must be amenable to treatment with a single study device\n4. Target lesion stenosis ≥ 50% and \\\u003C 100% by operator visual estimation, which may be assisted by QCA \u002F IVUS \u002F OCT. Target lesion stenosis \\\u003C 70% by visual estimation, should have clinical justification for treatment as per local standards.\n5. Target lesion must have a Thrombolysis in Myocardial Infarction (TIMI) flow ≥ 1\n\nClinical Exclusion Criteria:\n\n1. Subject is pregnant and\u002For breastfeeding or intends to become pregnant during the duration of the study\n2. Subject has clinical symptoms and\u002For electrocardiogram (ECG) changes consistent with STEMI \\\u003C 72 hours prior to the index procedure Note: Hemodynamically stable non-STEMI (NSTEMI) subjects are eligible for study enrollment\n3. Subject has undergone prior PCI within the target vessel during the last 12 months prior to the index procedure or prior PCI within a non-target vessel \\\u003C 72 hours prior to the index procedure\n4. Subject is on dialysis or has impaired renal function (serum creatinine \\> 2.5 mg\u002FdL or 221 µmol\u002FL, determined within 7 days prior to the index procedure)\n5. Subject has a known allergy to contrast medium that cannot be adequately premedicated, or any known allergy to aspirin, P2Y12 inhibitors, both heparin and bivalirudin, sirolimus, everolimus (or similar limus drugs), poly L-lactide, the scaffold material (magnesium, aluminum, tantalum), or Xience stent material (cobalt, chromium, tungsten, nickel, methacrylic polymer, and fluoropolymer)\n6. Subject is receiving oral or intravenous immunosuppressive therapy (inhaled steroids are permitted) or has known life-limiting immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus; diabetes mellitus is permitted)\n7. Life expectancy less than 1 year\n8. Planned surgery or dental surgical procedure within 6 months after index procedure, unless DAPT can be maintained\n9. In the investigator's opinion subject will not be able to comply with the follow-up requirements\n10. Subjects under oral anticoagulation therapy (OAC) prior to index procedure unless DAPT + OAC (i.e., triple therapy) can be maintained for a minimum of 1 month\n11. Subject has had a stroke or transient ischemic attack (TIA) within 6 months prior to the index procedure\n12. Subject with active bleeding disorder, active coagulopathy, or any other reason, who is ineligible for DAPT\n13. Subject is currently participating or plans to participate in another study with an investigational device or an investigational drug\n14. Subject has known severe aortic or mitral valve stenosis\u002Finsufficiency or has previously undergone transcatheter aortic valve replacement (TAVR)\n\nAngiographic Exclusion Criteria:\n\n1. Target vessel has been previously treated and the target lesion is within 5 mm proximal or distal to the previously treated lesion\n2. Left main coronary artery disease\n3. Target lesion is totally occluded (100% stenosis)\n4. Thrombus in target vessel\n5. Future planned staged PCI either in target or non-target vessel\n6. Ostial target lesion within the left anterior descending (LAD), left circumflex (LCX), or right coronary artery (RCA) (within 5.0 mm of vessel origin)\n7. Target lesion involves a side branch ≥ 2.0 mm in diameter that requires a two-device strategy after pre-dilatation\n8. Target lesion is located in or supplied by an arterial or venous bypass graft\n9. Target lesion with excessive tortuosity proximal to or within the lesion based on visual estimation or heavily calcified target lesion which cannot be adequately pre-dilated by a non-compliant and\u002For cutting\u002Fscoring balloon as described in angiographic exclusion criteria 10\n10. Target lesion requires treatment with a device other than the non-compliant balloon and\u002For cutting\u002Fscoring balloon prior to scaffold\u002Fstent placement (including but not limited to atherectomy devices, intravascular lithotripsy, drug-coated balloons, etc.)\n11. Target vessel was treated with brachytherapy any time prior to the index procedure.\n12. Unsuccessful pre-dilatation, defined as residual stenosis \\> 20% (by visual estimation) and\u002For angiographic complications (e.g., distal embolization, side branch closure, flow-limiting dissections)",{"count":571,"type":21},1859,[164],"The objective of this study is to assess the safety and efficacy of the Freesolve resorbable magnesium scaffold (RMS) in the treatment of subjects with up to two de novo lesions in native coronary arteries compared to the Xience coronary drug-eluting stent (DES) system",[575,576,32,577,578,117,579,580,581,582,583,584,585,586,587],"Coronary Disease","Heart Diseases","Arteriosclerosis","Arterial Occlusive Diseases","Chest Pain","Pain","Neurologic Manifestations","Signs and Symptoms","Pathological Conditions, Signs and Symptoms","Coronary Artery Disease","Myocardial Ischemia","Acute Coronary Syndrome","Angina Pectoris",[589,590,591,592],"Resorbable Magnesium Scaffold","Sirolimus","RMS","Drug eluting absorbable metal scaffold","2026-06-15",{"date":557,"type":40},{"date":596,"type":40},"2026-06-11",{"date":598,"type":21},"2033-06",{"name":600,"class":178},"Teleflex",{"id":602,"slug":4,"hasResults":11,"nctId":603,"briefTitle":604,"officialTitle":605,"acronym":606,"eligibilityCriteria":607,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":608,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":610,"conditions":611,"keywords":612,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":616,"startDateStruct":617,"completionDateStruct":619,"leadSponsor":621,"locationsCount":48},"100547514","NCT06408961","EVOC - EVs in Obesity and Cardiometabolic Disease","Extracellular Vesicle Signaling in Obesity and Cardiometabolic Disease (EVOC)","EVOC","Inclusion Criteria:\n\n* Age greater than or equal to 18 years of age\n* Obese (BMI\\>\u002F=30 kg\u002Fm2; for obesity\u002Fbariatric surgery group)\n* For 20 patients, additional criteria will be presence of pre-diabetes or diabetes (HgbA1c \\> 5.7 or Fasting blood glucose \\> 100).\n\nExclusion Criteria:\n\n* Pregnancy (as adjudicated by patient history)\n* Prior clinical history of myocardial infarction or valvular heart disease",{"count":609,"type":21},100,"The goal of this observational study is to research the impact of molecular signals from the heart, liver and fat tissue on cardiovascular disease risk, and the presentation of Type II Diabetes and diseases that affect the heart, blood vessels and metabolism (Cardiometabolic Disease). Specifically, the focus is on the content and function of Extracellular Vesicles (EVs), small sacs released from a cell's surface that contain important molecular cargo. The main questions it aims to answer are:\n\n1. What molecular cargo do adipose-tissue EVs carry?\n2. How do these cargo impact cardiac and hepatic function?\n3. Are changes in EV content related to cardiac function and adiposity with weight loss?\n\nTissue samples from fat tissue and blood samples will be collected from patients receiving bariatric weight loss surgery.",[32],[613,614,306,615],"Extracellular Vesicles","Cardiometabolic Disease","Type II Diabetes",{"date":557,"type":40},{"date":618,"type":40},"2019-02-02",{"date":620,"type":21},"2028-07-01",{"name":622,"class":73},"Massachusetts General Hospital",{"id":624,"slug":4,"hasResults":11,"nctId":625,"briefTitle":626,"officialTitle":627,"acronym":4,"eligibilityCriteria":628,"healthyVolunteers":11,"sex":16,"minAge":629,"maxAge":362,"enrollmentInfo":630,"targetDuration":4,"studyType":22,"phases":632,"briefSummary":633,"conditions":634,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":637,"startDateStruct":639,"completionDateStruct":641,"leadSponsor":643,"locationsCount":48},"100633239","NCT07524101","Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD","Utilizing Lipid-lowering Therapy With Moderate-intensity Statin Plus Ezetimibe in Chronic Kidney Disease Patients With Concomitant Atherosclerotic Cardiovascular Disease: ULTRA-CKD Trial","Inclusion Criteria:\n\n1. Age 19-85 years.\n2. Chronic kidney disease stage III, IV, or V (CKD-EPI eGFR \\\u003C60 \u002F \\\u003C30 \u002F \\\u003C15 mL\u002Fmin\u002F1.73 m² or on dialysis).\n3. Established ASCVD, meeting at least one of the following:\n\n   * Prior acute coronary syndrome (myocardial infarction or unstable angina).\n   * Stable angina confirmed by imaging studies.\n   * History of coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting).\n   * Peripheral artery disease.\n   * Ischemic stroke or transient ischemic attack.\n\nExclusion Criteria:\n\n1. Baseline LDL cholesterol \\\u003C55 mg\u002FdL in the absence of statin therapy.\n2. Acute liver disease or persistently unexplained serum AST\u002FALT ≥2 × the upper limit of normal.\n3. Allergy or hypersensitivity to statins.\n4. Life expectancy \\\u003C1 year.\n5. Expected inability to complete at least 1 year of follow-up.\n6. Inability to read or understand the informed consent form.","19 Years",{"count":631,"type":21},1952,[164],"The ULTRA-CKD trial is a prospective, randomized, open-label, multicenter trial designed to compare the efficacy and safety of moderate-intensity statin plus ezetimibe combination therapy versus high-intensity statin monotherapy in patients with chronic kidney disease (CKD) and concomitant atherosclerotic cardiovascular disease (ASCVD).\n\nPatients with CKD are at very high risk for ASCVD. In this population, it is important to establish a lipid-lowering strategy that optimizes cardiovascular outcomes while ensuring long-term safety. While high-intensity statins are generally considered as initial treatment option for secondary prevention, the optimal strategy for CKD patients remains to be clinicaly defined. This study aims to evaluate whether the combination of moderate-intensity statin and ezetimibe is non-inferior to high-intensity statin monotherapy in terms of 3-year composite of major adverse cardiovascular events.",[394,225,635,636,32],"Dyslipidemia","Hypercholesterolemia",{"date":638,"type":40},"2026-06-16",{"date":640,"type":40},"2026-05-28",{"date":642,"type":21},"2031-01-22",{"name":644,"class":73},"Yonsei University",{"id":646,"slug":4,"hasResults":11,"nctId":647,"briefTitle":648,"officialTitle":648,"acronym":4,"eligibilityCriteria":649,"healthyVolunteers":54,"sex":16,"minAge":17,"maxAge":650,"enrollmentInfo":651,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":653,"conditions":654,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":656,"lastUpdatePostDateStruct":657,"startDateStruct":658,"completionDateStruct":660,"leadSponsor":662,"locationsCount":48},"100392357","NCT04388943","Biomedical Research Informatics Centre for Cardiovascular Sciences (The BRICCS Study)","Inclusion Criteria:\n\n* All outpatients and inpatients with cardiovascular disease, of either gender\n* Aged 18-90 years old\n* Examples of conditions include: coronary artery disease, heart failure, heart attacks (myocardial infarction), valve disease, cardiac surgery, dysrhythmias (including atrial fibrillation), aneurysms, embolism, strokes, peripheral vascular disease, hypertension (and its complications, such as left ventricular hypertrophy) or those presenting with chest pain\n* Healthy volunteers\n* Aged 18-90 years old\n* From the community without cardiovascular or other diseases\n\nExclusion Criteria:\n\n* Any patient who is unable to give consent\n* Any patient with non-cardiovascular comorbidity likely to cause death within 6 months\n* Patients know to be infected with HIV, Hepatitis B or any other agent posing an infection risk from unfixed material","90 Years",{"count":652,"type":21},9500,"This project will examine the diagnosis and prognosis of patients with cardiovascular disease in hospital in- and outpatients and compare their characteristics with normal controls from the community. The cardiovascular diseases studied include coronary artery disease, heart failure, heart attacks, valve disease, cardiac surgery, dysrhythmias, aneurysms, embolism, strokes, peripheral vascular disease and hypertension. Current methods for diagnosis and predicting outcome in patients are limited and may lack accuracy. This study will collect clinical details, and blood and urine samples from patients for analysis of proteins, chemicals and genetic biomarkers which will enable an examination of the pathological mechanisms involved in cardiovascular disease. The data will also be used to improve diagnosis and also improve prediction of outcome in patients (future clinical events such as death, further hospitalisation with cardiovascular disease and the effects of any therapy given to the patients). In this way, we can develop accurate ways of assessing a patient's condition and how it could be effectively managed. The study will last for 20 years.",[32,655],"Cardiovascular Risk Factor","2026-06-10",{"date":596,"type":40},{"date":659,"type":40},"2010-06-17",{"date":661,"type":21},"2027-03-31",{"name":663,"class":73},"University Hospitals, Leicester",""]